After a successful overseas festival in Sydney, Australia, SXSW will head to London in 2025. Photo courtesy of SXSW

Get ready to see triple in 2025: South by Southwest (SXSW) is heading across the pond for its first-ever conference in London in June 2025.

According to a press release, the new European festival and conference will aim to showcase London's "status as a global meeting place." Much like the original Austin festival, SXW London will occupy dozens of galleries, clubs, and other event venues throughout Shoreditch – located in east London – for its conference sessions, exhibitions, film screenings, activations, music showcases, and much more.

"SXSW London will build on Austin's incredible legacy, presenting an event that underpins why SXSW is the go-to destination for professionals and creatives seeking meaningful connections, unexpected experiences and ideas that can help shape the world," said SXSW London managing director Randel Bryan in the release.

SXSW held its first overseas festival in Sydney, Australia in 2023; The festival counted more than 287,000 attendees, encouraging leadership and organizers to expand further outside of the U.S.

London was a clear-cut choice thanks to the city's diversity, economy, and innovation. The release said the United Kingdom's cultural and creative industries alone generate £125 billion (over $156 billion), with more than half of that revenue coming from London.

Sadiq Kha, the mayor of London, said in a statement that he was inspired to facilitate a partnership with SXSW after visiting Austin during the 2018 festival.

"This is a historic opportunity for London to once again bring the world’s most exciting talent together as part of our mission to build a better and more prosperous London for everyone," Kha said.

While official festival dates are still under wraps, the release says badges are expected to go on sale in October 2024. More information about SXSW London 2025 can be found on sxswlondon.com.

------

This article originally ran on CultureMap.

Two Houston companies will be pitching at SXSW in March hoping to win their categories and take home "Best of Show." Marie Ketring/via sxsw.org

2 Houston companies named pitch finalists for SXSW 2019

Headed to ATX

In two months, a couple Houston companies will be packing their bags and headed for Austin, where they will pitch their startups at the 11th annual SXSW Pitch event. SXSW announced the 50 finalists on Wednesday.

A total of six Texas companies — two from Houston and four from Austin — will be presenting to a live audience and panel of judges at the March 9 to 10 competition. There are 10 categories, each with one winner, as well as an overall "Best of Show" winner.

Houston-based Fluidity Technologies will be presenting as its drone controller, FT Aviator, has been named a finalist in the Hyper-Connected Communities category. Fluidity is lead by CEO Scott Parazynski, a former NASA astronaut, pilot, and physician. The FT Aviator has the potential to revolutionize drone technology. The joystick-like controller is based off movement in space, Parazynski says, and is less prone to user error by someone not as well trained in drone operation.

"I've flown aircraft and spacecraft," Parazynski says in an InnovationMap article about the company. "But none allowed for the precision of motion I was looking for. None prevented unintended motion."

The other Houston company selected as a finalist is Zibrio SmartScale, which is in the Health and Wearable category. The company is all about balance. Its product, a smart scale that tracks balance, aims to reduce dangers that come with poor balance — injuries, deaths, and costs from falls. Katharine Forth leads the company as CEO and founder. The company was a member of TMCx's 2015 medical devices cohort.

SXSW's competition this year has expanded to include new categories and has seen an increase in startups.

"We have seen a 42 percent rise in applicants coming out of last year's event, and we couldn't be more thrilled to see such an impressive increase in the value of SXSW Pitch among the tech industry's most innovative startups," says SXSW Pitch Event Producer Chris Valentine in the release. "In addition to the creation of the new AI and blockchain categories, we've also expanded our advisory board to highlight geographic, gender, and racial inclusion – accelerating our desire to represent the world's most innovative and successful leaders in all areas of technology."

It's not just in the finalists that Houston is represented — two advisers are from the Bayou City. Mariam Jacob, of Allergy and Asthma Clinics of Houston, will be a pre-event coach, and Gabriella Rowe, CEO of Station Houston, will be an on-site coach.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.